. 2019 May 24;20(10):2560. doi: 10.3390/ijms20102560

Table 2.

Immune–related endocrine toxicities.

	Anti-CTLA-4 (Prevalence of the Disease: %)	Refs.	Anti PD-1/Anti PD-L1 (Prevalence of the Disease: %)	Refs.	Combination (Prevalence of the Disease: %)	Refs.
Hypophysitis	0–17 with Ipilimumab	[44,47]	<1	[2,3]	not increased in comparison to monotherapy results	[50]
Hypophysitis	0.4–5 with Tremelimumab	[47,48]	<1	[2,3]	not increased in comparison to monotherapy results	[50]
Hypothyroidism	4.3–11.0 secondary hypothyroidism	[45,51,52]	5.9	[45]	22	[49]
Hypothyroidism	5.2–5.9 primary hypothyroidism	[53,54,55,56,57,58,59,60,61,62]	5.9	[45]	17 of any grade	[63,64]
Hyperthyroidism	2	[38]	1.0–4.7	[45]	10 of any grade	[63,64]
Diabetes	0	[38]	0–1	[38]	NR	[38]
Adrenalitis	<2	[38]	<2	[38]	<2	[38]